Latest filings (excl ownership)
10-K
2023 FY
Annual report
15 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Entry into a Material Definitive Agreement
27 Mar 24
8-K
Entry into a Material Definitive Agreement
22 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9 Nov 23
D
$700.00 k in Convertible Debt, sold $700.00 k, 2 investors
20 Oct 23
8-K
Entry into a Material Definitive Agreement
13 Oct 23
8-K
Departure of Directors or Certain Officers
13 Oct 23
ARS
2022 FY
Annual report to shareholders
8 Sep 23
DEF 14A
Definitive proxy
8 Sep 23
8-K
Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules
5 Sep 23
PRE 14A
Preliminary proxy
29 Aug 23
8-K
Avalon’s Laboratory Services MSO Announces Expansion into Arizona
21 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Avalon’s Laboratory Services MSO Acquires Texas Lab with Significant Potential Growth
24 Jul 23
8-K
Regulation FD Disclosure
19 Jul 23
8-K
Entry into a Material Definitive Agreement
7 Jul 23
424B3
Prospectus supplement
29 Jun 23
EFFECT
Notice of effectiveness
29 Jun 23
CORRESP
Correspondence with SEC
27 Jun 23
UPLOAD
Letter from SEC
22 Jun 23
S-3
Shelf registration
16 Jun 23
8-K
Entry into a Material Definitive Agreement
16 Jun 23
8-K
Entry into a Material Definitive Agreement
26 May 23
8-K/A
Financial Statements and Exhibits
26 May 23
10-Q
2023 Q1
Quarterly report
22 May 23
NT 10-Q
Notice of late quarterly filing
16 May 23
8-K
Avalon GloboCare Reports Laboratory Services MSO Revenue of $14.7 Million and Net Income of $6.3 Million in 2022
27 Apr 23
8-K/A
Financial Statements and Exhibits
26 Apr 23
10-K
2022 FY
Annual report
30 Mar 23
RW
Registration withdrawal request
22 Mar 23
8-K
Transaction Expected to Be Accretive to Earnings Through Profit Sharing Agreement
13 Feb 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Jan 23
8-K
Avalon GloboCare Appoints Lourdes Felix, CEO of a Premier Addiction Treatment Company, to its Board of Directors
11 Jan 23
8-K
Material Modifications to Rights of Security Holders
4 Jan 23
8-K
Submission of Matters to a Vote of Security Holders
30 Dec 22
8-K
Entry into a Material Definitive Agreement
14 Dec 22
DEFA14A
Additional proxy soliciting materials
12 Dec 22
DEF 14C
Information statement
25 Nov 22
Latest ownership filings
SC 13D/A
Lu Wenzhao
24 Jan 24
4
W J Tauzin
9 Mar 23
4
Steven Andrew Sanders
9 Mar 23
4
William B. Stilley III
8 Mar 23
4
Tevi Troy
8 Mar 23
3
Lourdes Felix
7 Mar 23
4
Wenzhao Lu
8 Aug 22
4/A
Wenzhao Lu
27 Jul 22
4/A
Wenzhao Lu
26 Jul 22
4
Wenzhao Lu
21 Jul 22
4
Wenzhao Lu
3 Apr 20
4
Wenzhao Lu
25 Feb 20
4
Tevi Troy
25 Feb 20
4
William B. Stilley III
25 Feb 20
4
Steven Andrew Sanders
25 Feb 20
4
Yancen Lu
25 Feb 20
4
Yue Charles Li
25 Feb 20
4
Meng Li
25 Feb 20
4
David Jin
25 Feb 20
4
Luisa Ingargiola
25 Feb 20
4
Wenzhao Lu
7 Jun 19
4
Wenzhao Lu
6 Jun 19
4/A
Wenzhao Lu
24 Apr 19
4
Wenzhao Lu
22 Apr 19
SC 13D/A
Avalon GloboCare Corp.
22 Apr 19
3
Yue Charles Li
19 Apr 19
4
Meng Li
9 Apr 19
3
Steven Andrew Sanders
31 Jul 18
3
William B. Stilley III
10 Jul 18
3
Tevi Troy
14 Jun 18
4
Steven Philip Sukel
19 Jan 18
4
Steven Philip Sukel
4 Jan 18
4
Steven Philip Sukel
4 Jan 18
3
W J Tauzin
15 Nov 17
3
Yancen Lu
2 Aug 17
SC 13D
Avalon Globocare Corp.
2 Aug 17
SC 13D
Avalon Globocare Corp.
2 Aug 17
3
Steven Philip Sukel
8 May 17
SC 13D/A
Avalon Globocare Corp.
20 Apr 17
4
Wenzhao Lu
20 Apr 17